Literature DB >> 33561612

Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis.

Marika Falla1, Alessio Di Fonzo2, Andrew Anthony Hicks3, Peter Paul Pramstaller4, Giovanni Fabbrini5.   

Abstract

INTRODUCTION: Levodopa-induced dyskinesia frequently complicates long-term Parkinson's disease. More in-depth knowledge regarding the role of genetic factors in dyskinesia development may be important to identify parkinsonian patients who are more prone to developing dyskinesia and clarify the molecular mechanisms underlying this condition. For this reason, we systematically reviewed studies investigating genetic factors involved in dyskinesia.
METHODS: A systematic search of genetic factors in Parkinson's disease dyskinesia was performed using the MEDLINE (through PubMed up to June 2019) and EMBASE databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A meta-analysis was conducted using a random effect model.
RESULTS: The literature search retrieved 33 studies assessing genes and variants possibly associated with dyskinesia in Parkinson's disease. The studies were published between 1984 and 2019 and included a total of 27,092 subjects of different ethnicities. Overall, 37 genes were analyzed in the studies reviewed, of which 22 were possibly associated with dyskinesia. The studies reported a total of 158 variants, of which 94 were possibly related to dyskinesia.
CONCLUSION: The studies reviewed demonstrated inconsistent results, possibly due to differences in screening methods and in the comparison of clinical data in a large variety of genetically- and ethnically-diverse populations. The meta-analysis failed to demonstrate any association between the rs6280 in the DRD3 gene, rs1799836 in the MAO-B, rs4680 in the COMT gene, rs34637584 in the LRRK2 gene and LID susceptibility. The role of genetic factors in LID susceptibility is still unclear and further studies are required.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dopamine- or non-dopamine-mediated neurotransmission; Genetic polymorphism; Levodopa-induced dyskinesia; Parkinson's disease

Mesh:

Substances:

Year:  2021        PMID: 33561612     DOI: 10.1016/j.parkreldis.2021.01.020

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  6 in total

1.  Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Gita Vita Soraya; Zulvikar Syambani Ulhaq; Syifaus Shodry; Muhammad A'raaf Sirojan Kusuma; Sarah Herawangsa; Maharani Oryza Sativa; Aridin Gustaf; Dzakky Avecienna Nur Faridwazdi; Shinta Wulandari Florentia; Neila Raisa; Andi Kurnia Bintang; Muhammad Akbar
Journal:  Neurol Sci       Date:  2022-01-25       Impact factor: 3.307

2.  A Roadmap for Future Parkinson's Pharmacogenomics in Asia.

Authors:  Muhammad Akbar; Gita Vita Soraya; Zulvikar Syambani Ulhaq; Andi Kurnia Bintang
Journal:  Front Aging Neurosci       Date:  2022-05-17       Impact factor: 5.702

Review 3.  Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.

Authors:  Yanying Yin; Yang Liu; Meisong Xu; XiaoMin Zhang; Chen Li
Journal:  Neurol Sci       Date:  2021-08-04       Impact factor: 3.307

Review 4.  Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia.

Authors:  Andrea Fabbrini; Andrea Guerra
Journal:  J Exp Pharmacol       Date:  2021-04-29

5.  Functional MAOB Gene Intron 13 Polymorphism Predicts Dyskinesia in Parkinson's Disease.

Authors:  Matthias Löhle; Graziella Mangone; Wiebke Hermann; Denise Hausbrand; Martin Wolz; Julia Mende; Heinz Reichmann; Andreas Hermann; Jean-Christophe Corvol; Alexander Storch
Journal:  Parkinsons Dis       Date:  2022-01-20

6.  Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson's Disease Cohorts.

Authors:  Jodi Maple-Grødem; Kimberly C Paul; Ingvild Dalen; Kathie J Ngo; Darice Wong; Angus D Macleod; Carl E Counsell; David Bäckström; Lars Forsgren; Ole-Bjørn Tysnes; Cynthia D J Kusters; Brent L Fogel; Jeff M Bronstein; Beate Ritz; Guido Alves
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.